D-1584-2014 Class III Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-1584-2014 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Aug 25, 2014 and is designated Class III. Reason for recall: Failed Content Uniformity Specifications. The recall status is terminated (terminated May 18, 2018). Affected quantity: 1396 Bottles.

Recall details

Product Type
Drugs
Report Date
Sep 24, 2014
Initiation Date
Aug 25, 2014
Termination Date
May 18, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1396 Bottles

Product description

Warfarin Sodium Tablets, USP Crystalline, 2 mg, 100 and 1000 Tablet Bottles, Rx Only. Mfd. by: Taro Pharmaceutical Industries, Ltd., Haifa Bay, Israel 26110. Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. 100 Tablet Bottle NDC: 51672-4028-1, 1000 Tablet Bottle NDC: 51672-4028-3.

Reason for recall

Failed Content Uniformity Specifications.

Distribution pattern

United States including: OH, HI, NH, MS, IL, TX, CA.

Code information

Lot #: 149400, Expiry: January 2016; Lot #: 149649, Expiry: January 2016.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1584-2014
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1584-2014. Report a data issue: hello@regdatalab.com.